Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome

P. Maslak, S. Chanel, L. H. Camacho, S. Soignet, P. P. Pandolfi, I. Guernah, R. Warrell, Stephen D Nimer

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Epigenetic mechanisms underlying tumorigenesis have recently received much attention as potential therapeutic targets of human cancer. We designed a pilot study to target DNA methylation and histone deacetylation through the sequential administration of 5-azacytidine followed by sodium phenylbutyrate (PB) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Ten evaluable patients (eight AML, two MDS) were treated with seven consecutive daily subcutaneous injections of 5-azacytidine at 75mg/m2 followed by 5 days of sodium PB given intravenously at a dose of 200mg/kg. Five patients (50%) were able to achieve a beneficial clinical response (partial remission or stable disease). One patient with MDS proceeded to allogeneic stem cell transplantation and is alive without evidence of disease 39 months later. The combination regimen was well tolerated with common toxicities of injection site skin reaction (90% of the patients) from 5-azacytidine, and somnolence/fatigue from the sodium PB infusion (80% of the patients). Correlative laboratory studies demonstrated the consistent reacetylation of histone H4, although no relationship with the clinical response could be demonstrated. Results from this pilot study demonstrate that a combination approach targeting different mechanisms of transcriptional modulation is clinically feasible with acceptable toxicity and measurable biologic and clinical outcomes.

Original languageEnglish
Pages (from-to)212-217
Number of pages6
JournalLeukemia
Volume20
Issue number2
DOIs
StatePublished - Feb 1 2006
Externally publishedYes

Fingerprint

Azacitidine
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Histones
Therapeutics
Stem Cell Transplantation
DNA Methylation
Subcutaneous Injections
Epigenomics
Fatigue
4-phenylbutyric acid
Carcinogenesis
Skin
Injections
Neoplasms

Keywords

  • Acute myeloid leukemia
  • DNA methylation
  • Epigenetics
  • Hhistone deacetylation
  • Targeted therapy

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. / Maslak, P.; Chanel, S.; Camacho, L. H.; Soignet, S.; Pandolfi, P. P.; Guernah, I.; Warrell, R.; Nimer, Stephen D.

In: Leukemia, Vol. 20, No. 2, 01.02.2006, p. 212-217.

Research output: Contribution to journalArticle

Maslak, P. ; Chanel, S. ; Camacho, L. H. ; Soignet, S. ; Pandolfi, P. P. ; Guernah, I. ; Warrell, R. ; Nimer, Stephen D. / Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. In: Leukemia. 2006 ; Vol. 20, No. 2. pp. 212-217.
@article{8242666f8f6945c6956fa2e50a532b45,
title = "Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome",
abstract = "Epigenetic mechanisms underlying tumorigenesis have recently received much attention as potential therapeutic targets of human cancer. We designed a pilot study to target DNA methylation and histone deacetylation through the sequential administration of 5-azacytidine followed by sodium phenylbutyrate (PB) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Ten evaluable patients (eight AML, two MDS) were treated with seven consecutive daily subcutaneous injections of 5-azacytidine at 75mg/m2 followed by 5 days of sodium PB given intravenously at a dose of 200mg/kg. Five patients (50{\%}) were able to achieve a beneficial clinical response (partial remission or stable disease). One patient with MDS proceeded to allogeneic stem cell transplantation and is alive without evidence of disease 39 months later. The combination regimen was well tolerated with common toxicities of injection site skin reaction (90{\%} of the patients) from 5-azacytidine, and somnolence/fatigue from the sodium PB infusion (80{\%} of the patients). Correlative laboratory studies demonstrated the consistent reacetylation of histone H4, although no relationship with the clinical response could be demonstrated. Results from this pilot study demonstrate that a combination approach targeting different mechanisms of transcriptional modulation is clinically feasible with acceptable toxicity and measurable biologic and clinical outcomes.",
keywords = "Acute myeloid leukemia, DNA methylation, Epigenetics, Hhistone deacetylation, Targeted therapy",
author = "P. Maslak and S. Chanel and Camacho, {L. H.} and S. Soignet and Pandolfi, {P. P.} and I. Guernah and R. Warrell and Nimer, {Stephen D}",
year = "2006",
month = "2",
day = "1",
doi = "10.1038/sj.leu.2404050",
language = "English",
volume = "20",
pages = "212--217",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome

AU - Maslak, P.

AU - Chanel, S.

AU - Camacho, L. H.

AU - Soignet, S.

AU - Pandolfi, P. P.

AU - Guernah, I.

AU - Warrell, R.

AU - Nimer, Stephen D

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Epigenetic mechanisms underlying tumorigenesis have recently received much attention as potential therapeutic targets of human cancer. We designed a pilot study to target DNA methylation and histone deacetylation through the sequential administration of 5-azacytidine followed by sodium phenylbutyrate (PB) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Ten evaluable patients (eight AML, two MDS) were treated with seven consecutive daily subcutaneous injections of 5-azacytidine at 75mg/m2 followed by 5 days of sodium PB given intravenously at a dose of 200mg/kg. Five patients (50%) were able to achieve a beneficial clinical response (partial remission or stable disease). One patient with MDS proceeded to allogeneic stem cell transplantation and is alive without evidence of disease 39 months later. The combination regimen was well tolerated with common toxicities of injection site skin reaction (90% of the patients) from 5-azacytidine, and somnolence/fatigue from the sodium PB infusion (80% of the patients). Correlative laboratory studies demonstrated the consistent reacetylation of histone H4, although no relationship with the clinical response could be demonstrated. Results from this pilot study demonstrate that a combination approach targeting different mechanisms of transcriptional modulation is clinically feasible with acceptable toxicity and measurable biologic and clinical outcomes.

AB - Epigenetic mechanisms underlying tumorigenesis have recently received much attention as potential therapeutic targets of human cancer. We designed a pilot study to target DNA methylation and histone deacetylation through the sequential administration of 5-azacytidine followed by sodium phenylbutyrate (PB) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Ten evaluable patients (eight AML, two MDS) were treated with seven consecutive daily subcutaneous injections of 5-azacytidine at 75mg/m2 followed by 5 days of sodium PB given intravenously at a dose of 200mg/kg. Five patients (50%) were able to achieve a beneficial clinical response (partial remission or stable disease). One patient with MDS proceeded to allogeneic stem cell transplantation and is alive without evidence of disease 39 months later. The combination regimen was well tolerated with common toxicities of injection site skin reaction (90% of the patients) from 5-azacytidine, and somnolence/fatigue from the sodium PB infusion (80% of the patients). Correlative laboratory studies demonstrated the consistent reacetylation of histone H4, although no relationship with the clinical response could be demonstrated. Results from this pilot study demonstrate that a combination approach targeting different mechanisms of transcriptional modulation is clinically feasible with acceptable toxicity and measurable biologic and clinical outcomes.

KW - Acute myeloid leukemia

KW - DNA methylation

KW - Epigenetics

KW - Hhistone deacetylation

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=31444438952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31444438952&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2404050

DO - 10.1038/sj.leu.2404050

M3 - Article

C2 - 16357841

AN - SCOPUS:31444438952

VL - 20

SP - 212

EP - 217

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -